Mydriasert (Phenylephrine Hydrochloride, Tropicamide)

Phenylephrine Hydrochloride and Tropicamide, the active ingredients in Mydriasert, are mydriatic agents presented as eye drops for ocular use. They are used to dilate the pupil and induce cycloplegia during diagnostic eye examinations in patients requiring detailed retinal assessment.

GNH USA supplies Mydriasert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mydriasert is a mydriatic ophthalmic solution used to achieve pupil dilation and cycloplegia in various eye care settings.

Diagnostic eye examinations: provides reliable pupil dilation for retinal imaging and fundus evaluation. Pre‑surgical ophthalmic procedures: facilitates surgical access by widening the pupil. Pediatric refraction assessments: induces cycloplegia to allow accurate measurement of refractive error in children.

Mydriasert may cause several ocular and systemic reactions.

Common Side Effects: - Transient ocular burning or stinging sensation. - Redness of the conjunctiva. - Temporary blurred vision. - Mild headache. - Slight increase in intra‑ocular pressure.

Serious or Rare Side Effects: - Acute angle‑closure glaucoma. - Severe allergic reaction (e.g., rash, swelling, anaphylaxis). - Systemic hypertension or hypertensive crisis. - Cardiac arrhythmias. - Persistent mydriasis lasting beyond the expected duration.

Prior to using Mydriasert, consider the following safety measures.

Contraindicated in patients with narrow‑angle glaucoma: avoid use to prevent angle‑closure attacks. Use with caution in cardiovascular disease: monitor blood pressure and heart rate. Avoid in individuals with known hypersensitivity to phenylephrine or tropicamide: discontinue if reaction occurs. Pediatric use should be limited and dosage individualized by the prescriber. Store at room temperature: keep in the original container, protect from light and moisture.

Mydriasert can interact with other medications; review patient medication lists.

Major Interactions (Avoid): - MAO inhibitors: may potentiate hypertensive response. - Sympathomimetic agents (e.g., epinephrine): risk of excessive vasoconstriction. - Anticholinergic drugs: additive cycloplegic effect.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask tachycardia caused by phenylephrine. - Systemic antihypertensives: monitor blood pressure for additive effects.